Girl Born Deaf Finally Able To Talk With Her Mother After Gene Therapy Restores Nearly All Her Hearing

A seven-year-old girl born deaf has regained almost all her hearing and can now hold everyday conversations with her mother after receiving experimental gene therapy in China. Her improvement was recorded four months after treatment, according to researchers from Sweden's Karolinska Institutet and collaborating Chinese hospitals.
She was among 10 patients treated for an inherited form of deafness in a study published in Nature Medicine in July 2025 and received renewed attention in April 2026. Every participant in the study showed better hearing during the initial follow-up.
Seven-Year-Old Regains Hearing
The girl was one of the strongest responders to the treatment, with hearing recovering sufficiently for regular conversations at home. Researchers found that children aged five to eight generally experienced the greatest improvement. The results also showed that benefit was possible beyond early childhood, although the extent of recovery varied between participants.
The trial involved patients aged approximately 18 months to 24 years at five hospitals in China. Most began detecting sounds more easily within a month of treatment. By six months, average hearing thresholds had fallen from 106 to 52 decibels, meaning patients could hear considerably quieter sounds than before.
Rare Genetic Condition Causes Deafness
All 10 participants had mutations in both copies of a gene called OTOF, causing a condition known as autosomal recessive deafness 9. The gene is responsible for producing otoferlin, a protein needed to pass sound information from sensory cells in the inner ear to the auditory nerve.
Without enough functioning otoferlin, these signals cannot be transmitted normally, even when the ear detects sound. The condition accounts for only a portion of inherited deafness, so the same treatment cannot be assumed to help people whose hearing loss has different causes.
The treatment used a modified virus to carry a working copy of OTOF into the inner ear. Doctors administered it through the round window, a thin membrane near the base of the cochlea. Nine patients received one injection, while one received two, according to the published study.
Hearing Improvements and Safety
Researchers assessed hearing using standard sound-detection tests and measurements of the brain's response to sound. Their findings covered six to 12 months after treatment, rather than several years. The study was also small and had no untreated comparison group, limiting conclusions about long-term effectiveness.
Investigators recorded 162 mild or moderate adverse events across the 10 patients. The most commonly reported was a reduction in the percentage of neutrophils, white blood cells that help the body fight infections, according to the published study.
No serious adverse reactions were reported during the available follow-up, but the team plans to continue monitoring safety and hearing in the participants.
Other Gene Therapies Advance
Separate research published in April 2026 followed 42 people with OTOF-related deafness and found hearing improvements in 90% of participants, with monitoring extending up to two and a half years.
Later that month, US regulators approved Otarmeni, another gene therapy targeting the same condition. That approved product is different from the experimental treatment given to the seven-year-old girl, whose longer-term results have not yet been established.
Researchers are also investigating gene therapies for other forms of inherited deafness, including those linked to GJB2 and TMC1. A treatment targeting GJB2 entered early-stage human trials in 2026, while research involving TMC1 remains at an earlier stage.